PacBio

272 articles about PacBio

• PacBio to Present at 42nd Annual J.P. Morgan Healthcare Conference

  12/27/2023

  PacBio, a leading developer of high-quality, highly accurate sequencing solutions, announced that management will be presenting at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 1:30 PM PT in San Francisco, California.

• PacBio Announces the Retirement of David Botstein, Ph.D., from its Board of Directors

  12/11/2023

  PacBio announced today that David Botstein, Ph.D., a member of PacBio's Board of Directors, has retired from his position effective December 7, 2023.  

• MedGenome, in collaboration with PacBio, announces a de novo genome assembly and annotation grant to empower non-model organism research

  11/21/2023

  MedGenome, a global partner for comprehensive multiomics solutions, is pleased to announce a grant for De Novo Genome Assembly and Annotation, in collaboration with PacBio, a pioneer in long-read sequencing.

• PacBio to Present at Upcoming November 2023 Investor Conferences

  11/9/2023

  PacBio, a leading developer of high-quality, highly accurate sequencing solutions, announced that management will be participating in the following upcoming investor conferences:

• PacBio Announces HiFi Solves, a Global Consortium of Clinical Genomics Research Leaders

  11/2/2023

  PacBio, a leading developer of high-quality, highly accurate sequencing solutions, announced the creation of the HiFi Solves consortium.

• PacBio Enables Rare and Inherited Disease Research by Adding Tertiary Analysis Partners to PacBio Compatible

  11/1/2023

  PacBio, a leading developer of high-quality, highly accurate sequencing solutions, announced the addition of two tertiary analysis partners to PacBio Compatible.

• PacBio Announces Kinnex RNA Kits, Further Scaling HiFi Sequencing in Full-Length RNA, Single-Cell RNA and 16S rRNA Applications

  10/31/2023

  PacBio (NASDAQ: PACB) today announced it has begun taking orders for its groundbreaking Kinnex RNA kits, which increase throughput for full-length RNA, single-cell RNA, and 16S rRNA sequencing on PacBio's long-read sequencing systems to enable large-scale studies at a resolution difficult to attain with short-read RNA sequencing.

• PacBio Announces Third Quarter 2023 Financial Results

  10/30/2023

  PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2023.

• PacBio Announces Appointment of David Meline to Board of Directors

  10/16/2023

  PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of David Meline to its Board of Directors, effective October 13, 2023.

• PacBio Announces Complete Computational Workflow for Human Whole Genome Sequencing Data Analysis

  10/11/2023

  PacBio today announced the availability of PacBio WGS Variant Pipeline – a complete, standardized computational method for HiFi whole genome sequencing (WGS) data analysis.

• PacBio Announces Collaboration with Leading Library Preparation Automation Partners

  9/7/2023

  PacBio today announced that automation providers Hamilton, Integra, Revvity and Tecan have created fully automated protocols to prepare samples for sequencing on Revio and Sequel II and IIe systems.

• PacBio to Present at Upcoming Investor Conferences - August 09, 2023

  8/9/2023

  PacBio, a leading developer of high-quality, highly accurate sequencing solutions, announced that management will be participating in the following upcoming investor conferences:

• PacBio and GeneDx Launch Research Collaboration with the University of Washington to Study Long-Read Whole Genome Sequencing for Increased Diagnostic Yield in Neonatal Care

  8/7/2023

  PacBio and GeneDx today announced a research collaboration with the University of Washington to study the capabilities of HiFi long-read whole genome sequencing (WGS) to increase diagnostic rates in pediatric patients with genetic conditions.

• PacBio Reports Equity Incentive Awards to New Employees Under Nasdaq Listing Rule 5635(c)(4)

  8/5/2023

  PacBio announced that PacBio's Compensation Committee of the Board of Directors granted non-qualified stock options covering an aggregate of 100,000 shares of PacBio common stock and restricted stock units covering 184,700 shares of PacBio common stock to fourteen non-executive employees.

• PacBio Announces Second Quarter 2023 Financial Results

  8/2/2023

  PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2023.

• PacBio Begins Commercialization of the Onso Short-Read Sequencing System

  8/2/2023

  PacBio, a leading developer of high-quality, highly accurate sequencing solutions, announced that customer shipments of Onso short-read sequencing instruments will commence.

• PacBio to Report Second Quarter 2023 Financial Results on August 2, 2023

  7/19/2023

  PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its second quarter 2023 financial results on Wednesday, August 2, 2023, at 5:00 pm Eastern Time.

• Sampled Named a Certified Service Provider for PacBio

  7/11/2023

  Sampled today announced that it has been named a Certified Service Provider for PacBio, a leading developer of high-quality, highly accurate sequencing solutions, equipping Sampled to deliver the highest quality advanced sequencing technology services on PacBio’s technology.

• PacBio's Revio System Empowers Bioscientia to Scale Long-Read Whole Genome Sequencing and Unravel the Mysteries of Rare Disease

  6/28/2023

  PacBio today announced that Bioscientia  is using its Revio long-read sequencing systems to expand its genomics research projects and sequence several thousand human genomes per year.

• PacBio Announces a Private Convertible Exchange Transaction of $441 Million Principal Amount of 1.375% Convertible Senior Notes due 2030

  6/26/2023

  PacBio announced that it has entered into a privately negotiated exchange agreement with a holder of PacBio's outstanding 1.50% Convertible Senior Notes due 2028, pursuant to which PacBio will issue $441 million principal amount of its 1.375% Convertible Senior Notes due 2030 in exchange for $441 million principal amount of the 2028 Notes, in a transaction exempt from registration under the Securities Act of 1933, as amended, and the rules and regulations thereunder.